Nuvectis Pharma Inc at Cantor Fitzgerald Global Healthcare Conference Transcript
Good afternoon, everyone. Welcome back to the Cantor Global Healthcare Conference. My name is Rick Bienkowski, biotech analyst here on the research team. We are very happy to be hosting Nuvectis Pharmaceuticals for a formal presentation today. And today with us on stage, we have Ron Bentsur, President and CEO of the company. And with that, I will turn it over to Ron.
Thank you very much. I want to thank Cantor for inviting us to present at the conference. It's a pleasure to be here. My name is Ron Bentsur, and I'm the CEO of Nuvectis Pharma. And Nuvectis Pharma is a company that's focused on precision medicine for unmet medical needs in oncology, I will be making some forward-looking statements, so I do encourage anyone who's interested in the company to read our public disclosures and in particular, the risk factors section, which is available in our 2022 10-K.
So with that, let's talk about some key highlights for the company. The
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |